Share this on:
 E-mail
26
VIEWS
0
COMMENTS
 
SHARES
About this iReport
  • Not vetted for CNN

  • Click to view multivu's profile
    Posted February 27, 2014 by
    multivu

    More from multivu

    Mirvaso® Approved for Treatment of Facial Redness of Rosacea

     
    Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.

    Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.

    To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea

    What do you think of this story?

    Select one of the options below. Your feedback will help tell CNN producers what to do with this iReport. If you'd like, you can explain your choice in the comments below.
    Be and editor! Choose an option below:
      Awesome! Put this on TV! Almost! Needs work. This submission violates iReport's community guidelines.

    Comments

    Log in to comment

    iReport welcomes a lively discussion, so comments on iReports are not pre-screened before they post. See the iReport community guidelines for details about content that is not welcome on iReport.

    Add your Story Add your Story